S-acylimino-x-substituted-az-i

  • Inventors:
  • Assignees:
  • Publication Date: February 26, 1957
  • Publication Number: US-2783241-A

Abstract

Claims

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF THOSE HAVING THE GENERAL FORMULA:
; corresponding 2-sulfonyl chloride derivative. 2,783,241 S-ACYLIMINO -4- SUBSTITUTED-A -1,3,4-THIADI- AZOLINE-Z-SULFONAMIDES AND METHODS FOR THEIR PREPARATION Richard William Young, Riverside, Kathryn Helen Wood, Old Greenwich, and James Robert Vaughan, Jr., Darien, Conn., assignors to American Cyanamid Company, New York, N. Y., a corporation of Maine No Drawing. Application March 4, 1955, Serial No. 492,297 12 Claims. (Cl. 260306.8) This invention relates to a new series of organic compounds. More particularly, this invention is concerned with certain 5 acylimino 4 substituted-A l,3,4-thiadizoline-Z-sulfonamides and methods for their preparation. The sulfanarnide drugs have come into prominence in recent years with the discovery by Clapp and Roblin (U. S. Patent No. 2,554,816) that certain heterocyclic sulfonamides are desirable diuretic agents because of their ability to inhibit the enzyme carbonic anhydrase. Because of this property, these agents have found utility in the treatment of certain diseases associated with fluid retention in the body such as congestive heart failure. We have now discovered a new series of compounds which are also capable of inhibiting carbonic anhydrase. in vivo tests of these compounds indicate that they are longer-acting inhibitors and that therapeutic levels of these drugs may be maintained over a longer period of time resulting in greater diuresis. The tests also show that our compounds are able to penetrate into the cerebro spinal fluid through the bloodzbrain barrier and into the ocular fluid through the bloodzocular fluid barrier. For this reason they are superior to other known compounds of this class in the treatment of glaucoma and epilepsy. The compounds of the present invention may be represented by the following general formula: wherein R1 is a hydrogen atom, a lower alkyl or a monocyclic aralkyl substituent and R2 is a lower alkyl or a monocyclic aralkyl substituent. As examples of lower alkyl radicals may be given methyl, ethyl, propyl, isopropyl, butyl and isobutyl. Suitable aralkyl substituents are benzyl, a-phenethyl, phenylpropyl and phenylbutyl. Compounds of the present invention can be prepared by chlorinating the 5-acylimino-4-substituted-2-benzylmercapto-A -1,3,4-thiadiazoline starting material to the The chlolination may be accomplished by passing chlorine gas through either a suspension or a solution of the starting material in an aqueous acid. The latter is preferred since it enables the operator to determine quickly the point at which the reaction is complete by a color change from colorless to yellow whereas this point is difficult to determine when a suspension is employed. It is to be noted, however, that either form is suitable and may be em ployed with equal advantage. The resulting sulfonyl chloride is then converted to the corresponding sulfonamide upon treatment with ammonia in the form of liquid ammonia or ammonium hydroxide, diluted with water, filtered and the solution acidified with a mineral acid such as hydrochloric acid or sulfuric acid. The preferred medium forchlorinating the starting material is a aqueous solution of acetic acid in which the starting materials are completely soluble. If a higher concentration is used, as for example a33% solution, the starting materials will not dissolve and a suspension results. As mentioned above, because of the ease of manipulation it is preferred to employ solutions of the starting material. Other, and equally useful, carriers are hydrobromic acid and hydrochloric acid as well as the lower fatty acids such as formic, propionic or butyric. The mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid are also useful for this purpose. The starting materials employed in this invention-- namely theS acylimino-4-substituted-Z-benzylmercapto- A -1,3,4-thiadiazolines, may be prepared by alkylating the corresponding 2 acylamino-S-benzylmercapto-1,3,4- thiadiazole with an alkyl halide under suitable reaction conditions. Methyl iodide and benzyl bromide are examples of alkylating agents which may be used. The reaction is preferably conducted in the presence of a sodium alkoxide such as sodium methoxide. The details relating to the preparation of the starting material are completely set forth in the copending U. S. application S. N. 492,298 of Richard W. Young and Kathryn H. Wood, filed concurrently herewith. The utility of the present invention is illustrated by the following examples, which are intended to be merely illustrative and not limitative upon the scope thereof. . All parts are by weight unless otherwise specified. Example 1 A suspension of 6 parts by weight of 5-acetylimino-4- methyl-Z-beuzylmercapto-A 1,3,4 thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylirniuo-4-methyl A l,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from, hot water. Exampie II A 1.18 parts by Weight sample of S-acetyliminolbenzyl-2-benzylmercapto-A l,3,4-thiadiazoline was sus pended in 30 parts by volume of 33% acetic acid and the mixture chlorinated at 5 C. for 30 minutes. The solid sulfonyl chloride derivative was filtered off, washed with Water and dissolved in 50 parts by volume of ether. This solution was dried and added to about 10 parts by volume of liquid ammonia. The excess ammonia and solvent were removed by distillation and the residue was redissolved in cold water. On acidifying this solution, the crude 5-acetylimino-4-benZyl-A -1,3,4-thiadiazoline- 2-sulfonamide was precipitated as a colorless solid. The product was purified by crystallization twice from 50% ethanol and then from a mixture of ethyl acetate and petroleum ether. Example 111 A suspension of 6 parts by weight of 5-acetylimino-4- ethyl-Z-benzylmercapto-A -1,3,4-thiadiazoline in parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-acetylimino-4-ethyl-A -l,3,4-hiadiazoline-2-sulfonamide. The product was purified by two recrystallizations from hot water. Example IV A 1.18 parts by weight sample of 5-propionylimino-4- methyl-Z-benzylmercapto-A -1,3,4-thiadiazolinc was sus- Platented Feb. 26, pended in 30 parts by volume of 33% acetic acid and the mixture chlorinated at C. for 30 minutes. The solid sulfonyl chloride derivative was filtered off, washed with water and dissolvedin 50 parts by volume of ether. This solution was dried and added to about parts by volume of liquid ammonia. The excess ammonia and solvent were removed by distillation and the residue was redissolved in cold water. On acidifying this solution, the crude 5-propionyliinino-4-methyl-A -1,3,4-thiadiazoline- 2-sulf0namide was precipitated as a colorless solid. The product was purified by crystallization twice from 50% ethanol and then from a mixture of ethyl acetate and petroleum ether. Example V A suspension of 6 parts by weight of S-propionylimino- 4-ethyl-2-benzylmercapto-A -1,3,4-thiadiazoline in 180 parts by volume of 33% aqueous acetic acid was chlorinated at 5 C. for 30 minutes. The solid was filtered off, dried, and added portion-wise to 100 parts by volume of liquid ammonia. The ammonia was removed under a stream of dry nitrogen. The residual solid was partially dissolved in 10 parts by volume of water, filtered, and acidified to give 5-p1'opionylimino-4-ethyl-A -1,3,4- thiadiazoline-Z-sulfonamide. The product was purified by two recrystallizations from hot water. Example VI 14 parts by weight of 5-acetylimino-4-methyl-2-benzylmercapto-n -l,3,4-thiadiazoline was dissolved in a solution containing 150 parts by volume of glacial acetic acid and 50 parts by volume of water. The mixture was chlorinated for 10 minutes at 10 C. to 15 C. with chlorine gas until the colorless solution turned a permanent yellow color. The reaction mixture was poured into a mixture of 100 parts by volume of water and 100 parts by weight of ice. A white solid was immediately deposited and was filtered ofi. The dry solid was added to 75 parts by volume of liquid ammonia and the excess evaporated under nitrogen. The reaction mixture was diluted with 100 parts by volume of water, leaving a cloudy solution. Upon acidification with hydrochloric acid, a solid of 5-acetylimino-4-methyl-A -l,3,4-thiadiazoline 2 sulfonamide was deposited, which was filtered off and dried. Example VII Following the procedure set forth in Example VI, 5 acetylirnino-4-benzyl-2-benzylmercapto-A -l,3,4-thiadiazoline may be dissolved in a 10% solution of acetic acid and the mixture chlorinated for 10 minutes at 5 C., with chlorine gas until the solution turns a permanent yellow color. The sulfonyl chloride derivative is obtained by pouring the reaction mixture into a mixture of 100 parts by volume of water and 100 parts by weight of ice. The white solid which deposits, is filtered off. The dry solid is added to 75 parts by volume ofliquid ammonia and the excess is evaporated under nitrogen. Dilution with 100 parts by volume of water leaves a cloudy solution which, upon acidification with hydrochloric acid, yields 5-acetylimino-4-benzyl-A -l,3,4-thiadiazoline-Z-sulfonamide, which is filtered 06 and dried. The following listed compounds may be prepared by following the procedure described in Example I, employing as a starting material the appropriate 5-acylimino-4- substituted-Z-benzylmercapto-M-1,3,4-thiadiazoline: 5-formylimino-4methyl-A -1,3,4-thiadiazoline 2 sulfonamide 5 butyrylimino 4 methyl A 1,3,4 thiadiazoline- 2-su1fonamide 5 butyrylimino 4 benzyl A 1,3,4 thiadiazoline- 2-sulfonamide 5 acetylimino 4 p nitrobenzyl A 1,3,4 thiadiazoline-Z-sulfonamide 5 acetylimino 4 butyl A 1,3,4 thiadiazoline 2 sulfonamide 4 5 propionylimino 4 butyl A 1,3,4 thiadiazoline- 2-sulfonamide We claim: 1. A compound selected from the group consisting of those having the general formula: wherein R1 is a member selected from the group consisting of hydrogen atoms, lower 'alkyl and lower-alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of lower alkyl andphenyl-loweralkyl radicals. 2. The compound 5-acetylimino-4-methyl-A -l,3,4-thiadiazoline-Z-sulfonamide. 3. The compound 5-acetylimino-4-benzyl-A -l,3,4-thiadiazoline-Z-sulfonamide. 4. The compound 5 -acetylimino-4-cthyl-M-l,3,4-thiadiazoline-Z-sulfonamide. 5. The compound 5-propionylimino-4-methyl-A 1,3,4- thiadiazoline-Z-sulfonamide. 6. The compound 5 propionylimino-4-ethyl-A -l,3,4- thiadiazoline-Z-sulfonamide. 7. A method for preparing compounds selected from the group consisting of those having the general formula: Ric-Ni J8 OINHI wherein R1 is a member selected from the group consisting of hydrogen, lower alkyl and phenyl-lower-alkyl radicals and R2 is a member selected from the group consisting of the lower alkyl and phenyl-lower-alkyl radicals which comprises chlorinating a member selected from the group consisting of 5-acylimino-4-lower alkyl-Z-benzylrnercapto-A -1,3,4-thiadiazolines and 5 -acylimino-4- phenyl-loweralkyl- 2 -benzylmercapto-A -1,3,4'thiadiazolines in aqueous acid to, obtain the corresponding sulfonyl chloride derivative, and then reacting said derivative with ammonia. 8. A method for preparing 5-acetylimino-4-methyl-A l,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-methyl-2-benzylmercapto-A -1,3,- 4thiadiazoline in aqueous acid, and then reacting the resulting sulfonyl chloride derivative with ammonia. 9. A method 'for preparing 5-acetylimino-4-benzyl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-acetylimino-4-benzyl-2-benzylmercapto-A -1,3,- 4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia. 10. A method for preparing 5-acetylimino-4-ethylA l,3,4-thiadiazoline-2-sulfonamide which comprises chlo rinating 5 aceylimino-4-ethyl-2-benzylmercapto-n -1,3,4- thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia. 11. A method for preparing 5-propionyl-4methyl-A 1,3,4-thiadiazoline-2-sulfonamide which comprises chlorinating S-propionylimino-4-methyl-2-benzylmercapto-A 1,3,4-thiadiazoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia. 12. A method for preparing 5-propionyl-4-etl1yl-A 1,3,4-thiadiazoline-Z-sulfonamide which comprises chlorinating 5-propionylimino-4-ethyl-2-benzylrnercapto-A -1,- 3,4-thiadi-azoline in an aqueous acid and then reacting the resulting sulfonyl chloride derivative with ammonia. References Cited in the file of this patent UNITED STATES PATENTS 2,554,816 H ..Clapp et al.;. May 29, 1951

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    US-2554816-AMay 29, 1951American Cyanamid CoHeterocyclic sulfonamides and methods of preparation thereof

NO-Patent Citations (0)

    Title

Cited By (20)

    Publication numberPublication dateAssigneeTitle
    EP-2392567-A1December 07, 2011Bristol-Myers Squibb CompanyBenzothiazinderivate und ihre verwendung als lxr-modulatoren
    US-2006247272-A1November 02, 2006Pfizer Inc4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
    US-2011003740-A1January 06, 2011Verva Pharmaceuticals Ltd.Insulin sensitisers and methods of treatment
    US-2015150855-A1June 04, 2015Verva Pharmaceuticals LtdMethod of improving liver function
    US-2015174108-A1June 25, 2015Vera Pharmaceuticals LtdMethod of weight reduction
    US-2971909-AFebruary 14, 1961Standard Oil CoNon-corrosive lubricant compositions
    US-2978457-AApril 04, 1961Merck & Co Inc5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
    US-3157572-ANovember 17, 1964American Cyanamid CoParenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
    US-4264616-AApril 28, 1981Gulf Oil Corporation2-Iodoacetylimino-3-methyl-5-trifluoromethyl-1,3,4-thiadiazol-4-ine and use as a fungicide
    US-5776489-AJuly 07, 1998American Cyanamid CompanyControlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
    US-6878703-B2April 12, 2005Sankyo Company, LimitedPharmaceutical composition
    US-8455432-B2June 04, 2013Verva Pharmaceuticals Ltd.Insulin sensitisers and methods of treatment
    US-9452148-B2September 27, 2016Verva Pharmaceuticals LtdInsulin sensitisers and methods of treatment
    WO-2004017964-A1March 04, 2004Pfizer Products Inc.Therapie de combinaison pour maladies hyperproliferatives
    WO-2007062314-A2May 31, 2007Bristol-Myers Squibb CompanyHeterocyclic cetp inhibitors
    WO-2008070496-A2June 12, 2008Bristol-Myers Squibb CompanyN- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
    WO-2008089521-A1July 31, 2008Verva Pharmaceuticals LtdSensibilisateurs a l'iinsuline et procédés de traitement
    WO-2014170786-A1October 23, 2014Pfizer Inc.N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
    WO-2015012205-A1January 29, 2015第一三共株式会社Medicine for preventing or treating hypertension
    WO-2016055901-A1April 14, 2016Pfizer Inc.Composés d'amide substitué